4 research outputs found
Genetic Determinants of Surface Accessibility in <i>Staphylococcus aureus</i>
Bacterial
cell walls represent one of the most prominent targets
of antibacterial agents. These agents include natural products (e.g.,
vancomycin) and proteins stemming from the innate immune system (e.g.,
peptidoglycan-recognition proteins and lysostaphin). Among bacterial
pathogens that infect humans, Staphylococcus aureus (S. aureus) continues to impose a
tremendous healthcare burden across the globe. S. aureus has evolved countermeasures that can directly restrict the accessibility
of innate immune proteins, effectively protecting itself from threats
that target key cell well components. We recently described a novel
assay that directly reports on the accessibility of molecules to the
peptidoglycan layer within the bacterial cell wall of S. aureus. The assay relies on site-specific chemical
remodeling of the peptidoglycan with a biorthogonal handle. Here,
we disclose the application of our assay to a screen of a nonredundant
transposon mutant library for susceptibility of the peptidoglycan
layer with the goal of identifying genes that contribute to the control
of cell surface accessibility. We discovered several genes that resulted
in higher accessibility levels to the peptidoglycan layer and showed
that these genes modulate sensitivity to lysostaphin. These results
indicate that this assay platform can be leveraged to gain further
insight into the biology of bacterial cell surfaces
Systematic Assessment of Accessibility to the Surface of Staphylococcus aureus
Proteins from bacterial foes, antimicrobial
peptides, and host
immune proteins must navigate past a dense layer of bacterial surface
biomacromolecules to reach the peptidoglycan (PG) layer of Gram-positive
bacteria. A subclass of molecules (e.g., antibiotics with intracellular
targets) also must permeate through the PG (in a molecular sieving
manner) to reach the cytoplasmic membrane. Despite the biological
and therapeutic importance of surface accessibility, systematic analyses
in live bacterial cells have been lacking. We describe a live cell
fluorescence assay that is robust, shows a high level of reproducibility,
and reports on the permeability of molecules to and within the PG
scaffold. Moreover, our study shows that teichoic acids impede the
permeability of molecules of a wide range of sizes and chemical composition
pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity
A growing class of immunotherapeutics
work by redirecting components
of the immune system to recognize markers on the surface of cancer
cells. However, such modalities will remain confined to a relatively
small subgroup of patients because of the lack of universal targetable
tumor biomarkers among all patients. Here, we designed a unique class
of agents that exploit the inherent acidity of solid tumors to selectively
graft cancer cells with immuno-engager epitopes. Our targeting approach
is based on pHLIP, a unique peptide that selectively targets tumors in vivo by anchoring to cancer cell surfaces in a pH-dependent
manner. We established that pHLIP–antigen conjugates trigger
the recruitment of antibodies to the surface of cancer cells and induce
cytotoxicity by peripheral blood mononuclear and engineered NK cells.
These results indicate that these agents have the potential to be
applicable to treating a wide range of solid tumors and to circumvent
problems associated with narrow windows of selectivity
pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity
A growing class of immunotherapeutics
work by redirecting components
of the immune system to recognize markers on the surface of cancer
cells. However, such modalities will remain confined to a relatively
small subgroup of patients because of the lack of universal targetable
tumor biomarkers among all patients. Here, we designed a unique class
of agents that exploit the inherent acidity of solid tumors to selectively
graft cancer cells with immuno-engager epitopes. Our targeting approach
is based on pHLIP, a unique peptide that selectively targets tumors in vivo by anchoring to cancer cell surfaces in a pH-dependent
manner. We established that pHLIP–antigen conjugates trigger
the recruitment of antibodies to the surface of cancer cells and induce
cytotoxicity by peripheral blood mononuclear and engineered NK cells.
These results indicate that these agents have the potential to be
applicable to treating a wide range of solid tumors and to circumvent
problems associated with narrow windows of selectivity
